Ezetimibe API (CAS No. 163222 33 1) is a high purity cholesterol absorption inhibitor Active Pharmaceutical Ingredient widely used in lipid management formulations.
Ezetimibe works by selectively blocking intestinal absorption of cholesterol, helping reduce:
• Total cholesterol (TC)
• LDL C (“bad” cholesterol)
• Apo B (atherogenic marker)
• Non HDL C
It is extensively used in formulations for primary hyperlipidemia, familial hypercholesterolemia, and in fixed dose combinations with statins for enhanced lipid control.
Its strong efficacy, safety profile, and synergistic compatibility with statins make it one of the most prescribed modern lipid lowering APIs.
Specifications & Details
• Product Name: Ezetimibe
• Synonyms: Ezetimibe
• Product Code: ATM007EZTM
• Grade: USP / In house
• CAS Number: 163222 33 1
• Molecular Formula: C24H21F2NO3
• Molecular Weight: 409.4 g/mol
• COA & MSDS: Available on request
Packaging:
Export worthy air tight HDPE containers with double liner bags
Storage Condition:
Store in air tight containers
Protect from direct light and moisture
Key Features
• Manufactured in WHO GMP compliant facilities
• High purity cholesterol absorption inhibitor API
• Excellent stability and impurity control
• Suitable for tablets, capsules & fixed dose combinations
• Export grade quality with batch wise consistency
• Full regulatory documentation (COA, MSDS) available
Applications
Used in pharmaceutical formulations for:
• Primary hyperlipidemia
• Familial hypercholesterolemia
• Adjunct therapy with statins
• Fixed dose lipid lowering combinations
• Cardiovascular risk reduction strategies
Ezetimibe API, Cholesterol Absorption Inhibitor, Lipid Lowering Bulk Drug, Hyperlipidemia Treatment Ingredient, Cardiovascular API, Active Pharmaceutical Ingredient, CAS 163222 33 1, USP Grade, WHO GMP Certified, Pharmaceutical Export.
#Ezetimibe
#PharmaceuticalAPI
#CholesterolControl
#LipidLoweringAPI
#Hyperlipidemia
#BulkDrugs
#ActiveIngredient
#PharmaExport
#CAS163222331
#USPGrade











Reviews
There are no reviews yet.